Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback